QAD Upgrade Offers Strategic Support for Life Sciences Manufacturing Company Growth
Laerdal Medical Upgrades to QAD Enterprise Application
SANTA BARBARA, Calif.—June 21, 2012—QAD Inc. (NASDAQ:QADA)(NASDAQ:QADB), a leading provider of enterprise software and services for global manufacturing companies, announced today that Laerdal A/S, a leading manufacturer of CPR equipment and resuscitation training devices, is deploying the latest edition of QAD Enterprise Applications across their global operations.
“The latest release of QAD Enterprise Applications offered so many new capabilities making it easy to arrive at the decision to upgrade,” said Egil Mathisen, CFO, Laerdal Medical “In addition to the functionality offered by the solution, QAD’s industry knowledge of the medical device marketplace will help us to rapidly implement a global core model across all of our sites utilizing QAD’s best practice process maps.”
Laerdal chose to upgrade to QAD Enterprise Applications due to its ability to support flexible business processes across multiple business entities. Additionally, QAD’s Enterprise Applications supports multiple languages and internationalization which will support Laerdal’s global growth plans.
QAD’s solution supports critical requirements needed for life sciences manufacturing companies who must demonstrate regulatory compliance to current good manufacturing practice (cGMP). In particular, supporting Corrective and Preventative Actions (CAPA), eSignature, Device History Records as well as tools to assist in validation.
The QAD Enterprise Applications deployment will give Laerdal access to QAD’s market leading .NET User Interface and enable its users to achieve greater personal productivity. With built-in Analytics and Reporting, QAD Enterprise Applications empower users to quickly view trends within the system and easily drill down into the data, providing the flexibility and accuracy needed to answer questions as they arise and make informed decisions.
“We are excited to see QAD Enterprise Applications Enterprise Edition align with our customers’ strategic goals,” said Steve Gardner, EMEA Vice President Sales & Marketing for QAD. “The application is designed to address the challenges our manufacturing customers are facing today – and to help get them ready for the economic recovery of tomorrow.”
Laerdal is a manufacturer of medical equipment and medical training products, Laerdal's CPR training manikin 'Resusci Anne' is widely used throughout the world. Laerdal has over the years established sales operations in 23 countries and manufacturing and R&D operation units in four different locations. The company has 1400 employees.
For more information, please visit http://www.laerdal.com.
QAD is a leading provider of enterprise applications for global manufacturing companies specializing in automotive, consumer, electronics, food and beverage, industrial and life sciences products. QAD applications provide critical functionality for managing manufacturing resources and operations within and beyond the enterprise, enabling global manufacturers to collaborate with their customers, suppliers and partners to make and deliver the right product, at the right cost and at the right time.
For more information about QAD, telephone +1 805-566-6000, or visit the QAD web site at www.qad.com.
“QAD” is a registered trademark of QAD Inc. All other products or company names herein may be trademarks of their respective owners.
Note to Investors: This press release contains certain forward-looking statements made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expects”, “believes”, “anticipates”, “could”, “will likely result”, “estimates”, “intends”, “may”, “projects”, “should”, and variations of these words and similar expressions are intended to identify these forward looking statements. Forward-looking statements are based on the company’s current expectations and assumptions regarding its business, the economy and future conditions. A number of risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements. These risks include, but are not limited to, evolving demand for the company's software products and products that operate with the company's products; the company's ability to sustain license and service demand; the company's ability to leverage changes in technology; the company's ability to sustain customer renewal rates at current levels; the publication of opinions by industry and financial analysts about the company, its products and technology; the reliability of estimates of transaction and integration costs and benefits; the entry of new competitors or new offerings by existing competitors and the associated announcement of new products and technological advances by them; delays in localizing the company's products for new or existing markets; the ability to recruit and retain key personnel; delays in sales as a result of lengthy sales cycles; changes in operating expenses, pricing, timing of new product releases, the method of product distribution or product mix; timely and effective integration of newly acquired businesses; general economic conditions; exchange rate fluctuations; and, the global political environment. In addition, revenue and earnings in the enterprise resource planning (ERP) software industry are subject to fluctuations. Software license revenue, in particular, is subject to variability with a significant proportion of revenue earned in the last month of each quarter. Given the high margins associated with license revenue, modest fluctuations can have a substantial impact on net income. Investors should not use any one quarter's results as a benchmark for future performance. For a more detailed description of the risk factors associated with the company and the industries in which it operates, please refer to the company's Annual Report on Form 10-K for fiscal 2013 ended January 31, 2013, and in particular, the section entitled “Risk Factors” therein, and in other periodic reports the company files with the Securities and Exchange Commission.